87 results
8-K
EX-99.1
FATE
Fate Therapeutics Inc
26 Feb 24
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4:03pm
is conducting a preclinical assessment of the potential for FT522 to induce CD19+ B-cell depletion across a range of autoimmune diseases, including without
8-K
EX-99.1
srpdhgf7vejccp
3 May 23
Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates
4:06pm
8-K
EX-99.1
zvpv43j9ftit3b
3 Aug 22
Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
4:03pm
8-K
EX-99.1
4bqrnxscj
28 Feb 22
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
4:06pm
8-K
EX-99.2
m45lgibme shnmmhla
14 Dec 21
Other Events
5:28pm
8-K
EX-99.1
gd3fer40lt7cz 9mpdi
14 Dec 21
Other Events
5:28pm
8-K
EX-99.1
ulg hjzpr78wr
4 Nov 21
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
4:07pm